A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome

What Was Tested

The paper reports a study of Secretin, published as a randomized controlled trial.

Although biologically-derived porcine secretin is approved for the diagnosis of Zollinger-Ellison Syndrome, it is no longer available in the United States.

Pure human and porcine secretins have now been synthesized and new drug applications have been filed with the Federal Drug Administration (FDA).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

In the current study the researchers compared secretin testing results in six confirmed Zollinger-Ellison Syndrome patients using the biologically-derived product and both synthetic products (human and porcine) in a three-way, randomized, single-blind Latin-squares crossover study.

How the Study Was Run

In design terms this was a randomized, single-blind and crossover study.

Because people in this Secretin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Secretin study one party knew the assignments and the other did not.

Each person switched between Secretin and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Gastrins, Gastrointestinal Agents, Secretin, Swine and Zollinger-Ellison Syndrome.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Secretin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the Secretin compound page, all human trials.